Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase IIa INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc. announced positive data from INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase IIa clinical trial of PLN-74809 in patients with idiopathic pulmonary fibrosis.